{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Day 42"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Day 180"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Day 270"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Year 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) of sCR (stringent complete response), CR (complete response), VGPR (very good partial response), PR (partial response)","groups":[{"description":"Participants who received NYESO-1ᶜ²⁵⁹T following ASCT","id":"OG000","title":"NYESO-1ᶜ²⁵⁹T Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received NYESO-1ᶜ²⁵⁹T following ASCT","reportingStatus":"POSTED","timeFrame":"Change from Baseline at Day 42, 100, 180, 270 and Year 1","title":"Number of Participants With Response Per International Myeloma Working Group (IMWG) 2011 Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}